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ABSTRACT
Background: Although there is general agreement that metformin should be used as first-line pharmacotherapy in pa-
tients with type 2 diabetes, uncertainty remains regarding the choice of second-line therapy once metformin is no longer 
effective. We conducted a systematic review and meta-analysis to assess the comparative safety and efficacy of all available 
classes of antihyperglycemic therapies in patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Methods: MEDLINE, EMBASE, BIOSIS Previews, PubMed and the Cochrane Central Register of Controlled Trials were 
searched for randomized controlled trials published in English from 1980 to October 2009. Additional citations were ob-
tained from grey literature and conference proceedings and through stakeholder feedback. Two reviewers independently 
selected studies, extracted data and assessed risk of bias. Key outcomes of interest were hemoglobin A1c, body weight, 
hypoglycemia, quality of life, long-term diabetes-related complications, serious adverse drug events and mortality. Mixed-
treatment comparison and pairwise meta-analyses were conducted to pool trial results, when appropriate.
Results: We identified 49 active and non-active controlled randomized trials that compared 2 or more of the following 
classes of antihyperglycemic agents and weight-loss agents: sulfonylureas, meglitinides, thiazolidinediones (TZDs), di-
peptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, insulins, alpha-glucosidase inhibitors, 
sibutramine and orlistat. All classes of second-line antihyperglycemic therapies achieved clinically meaningful reductions 
in hemoglobin A1c (0.6% to 1.0%). No significant differences were found between classes. Insulins and insulin secreta-
gogues were associated with significantly more events of overall hypoglycemia than the other agents, but severe hypogly-
cemia was rarely observed. An increase in body weight was observed with the majority of second-line therapies (1.8 to 3.0 
kg), the exceptions being DPP-4 inhibitors, alpha-glucosidase inhibitors and GLP-1 analogues (0.6 to −1.8 kg). There were 
insufficient data available for diabetes complications, mortality or quality of life.
Interpretation: DPP-4 inhibitors and GLP-1 analogues achieved improvements in glycemic control similar to those of 
other second-line therapies, although they may have modest benefits with respect to weight gain and overall hypoglycemia. 
Further long-term trials of adequate power are required to determine whether newer drug classes differ from older agents 
in terms of clinically meaningful outcomes.
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The  population  of  interest  consisted  of  adults  and 
children with T2DM requiring a second-line antihyper-
glycemic agent because of inadequate control (hemoglo-
bin  A1c  (HbA1c)  > 6.5%,  fasting  plasma  glucose  (FPG) 
> 7  mmol/L  or  2-hour  postprandial  glucose  (PPG)   
> 10  mmol/L)
1,2,8,16  on  metformin  monotherapy  or  be-
cause of intolerance to this therapy. Agents from the fol-
lowing drug classes marketed in Canada, the European 
Union or the United States as of October 2009 were as-
sessed:  sulfonylureas,  meglitinides,  thiazolidinediones, 
DPP-4 inhibitors, GLP-1 analogues, insulins and insulin 
analogues, alpha-glucosidase inhibitors and weight-loss 
agents (orlistat and sibutramine). Outcomes of interest 
included HbA1c, hypoglycemia, body weight, quality of 
life, long-term complications of diabetes, severe adverse 
events (drug related or otherwise) and mortality. Ran-
domized  controlled  trials  (RCTs)  with  active-therapy 
and placebo controls published in English were included 
if they were at least 4 weeks in duration and compared 
one or more relevant drugs either (1) added to metformin 
because of inadequate glycemic control with metformin 
alone or (2) replacing metformin because of intolerance. 
We included studies regardless of metformin dose or dur-
ation at baseline and regardless of treatment history be-
fore metformin monotherapy. 
Study selection, data extraction and quality assess-
ment were conducted independently by 2 reviewers. Risk 
of bias was assessed using the SIGN-50 instrument.
17
Statistical  methods.  Bayesian  mixed-treatment  com-
parison (MTC) meta-analysis was conducted for HbA1c, 
body weight and overall hypoglycemia, after careful as-
sessment of heterogeneity across trials in terms of subject 
characteristics, trial methodologies and treatment proto-
cols. We elected to perform Bayesian MTC meta-analyses 
for 2 reasons: (1) many of the available second-line anti-
hyperglycemic agents have not been compared directly 
with  one  another,  necessitating  indirect  comparisons 
between  treatments,  and  (2)  the  number  of  individual 
pairwise comparisons is unwieldy given the large num-
ber of treatment alternatives, hence summary effect es-
timates against a common comparator are likely to be of 
greater utility for clinical and policy decisions.
18 Pairwise 
meta-analyses were also conducted for these outcomes 
to enhance the acceptability of the findings among read-
ers unfamiliar with Bayesian meta-analysis and to assess 
consistency between direct and indirect effect estimates. 
Only  pairwise  direct  comparisons  were  conducted  for 
the remaining outcomes because either a limited num-
ber of studies were available or events were infrequent. 
All analyses were conducted at the drug-class level. Trial 
ype 2 diabetes mellitus (t2dm) is a progressive 
metabolic disease that causes significant morbidity 
and mortality worldwide. Clinical practice guide-
lines
1–8 recommend metformin as the first-line oral anti-
hyperglycemic drug in most patients with T2DM when 
glycemic control cannot be achieved by lifestyle interven-
tions. Although some guidelines advise the addition of 
sulfonylureas as second-line therapy when glycemic con-
trol is inadequate with metformin alone,
2,5,6,8 others
1,3,4,7 
lack recommendations regarding a preferred agent. 
The number of therapies available for T2DM has ex-
panded in recent years to include more expensive drug 
classes such as thiazolidinediones, glucagon-like pep-
tide-1  (GLP-1)  analogues  and  dipeptidyl  peptidase-4 
(DPP-4) inhibitors (see Appendix 1, available online). In-
creased use of newer, more expensive drugs, along with 
the rising incidence of T2DM, has significant budget-
ary  implications  for  health  systems,  as  evidenced  by 
the growth in the worldwide diabetes pharmaceutical 
market from US$3.8 billion in 1995 to US$17.8 billion 
in 2005.
9 Hence, there is a need to determine whether 
newer  agents  offer  significant  advantages  over  older 
therapies. The question of optimal second-line pharma-
cotherapy is particularly relevant given the large num-
ber of treatment options available. Existing systematic 
reviews of treatments for T2DM have limitations in this 
regard because they did not include newer drug classes 
or did not restrict their analyses to patients whose T2DM 
was inadequately controlled with metformin alone.
10–14 
As part of a larger initiative to identify and promote 
the optimal use of second-line antihyperglycemic agents 
in type 2 diabetes (www.cadth.ca/index.php/en/compus/
second-line-therapies-type-2-diabetes), we conducted a 
systematic review and meta-analysis to address the fol-
lowing research question: What is the comparative ef-
ficacy  and  safety  of  available  antihyperglycemic  drug 
classes for patients with T2DM inadequately controlled 
with metformin monotherapy?
Methods
This systematic review was conducted according to a 
protocol prepared in advance.
15 MEDLINE, MEDLINE 
In-Process & Other Non-Indexed Citations, EMBASE, 
BIOSIS  Previews,  PubMed  and  the  Cochrane  Central 
Register  of  Controlled  Trials  were  searched  through 
the Ovid interface to identify English-language clinical 
articles published from 1980 to May 2009 (Appendix 
2, available online). Monthly OVID AutoAlerts were re-
viewed from June to October 2009. Additional citations 
were obtained from grey literature and conference pro-
ceedings and through stakeholder feedback.
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employed a crossover design, studies that were < 1 year 
in duration and studies in which the baseline metformin 
dose was < 1500 mg/day.
Results
Study selection. Of 2743 citations identified in the lit-
erature search, 288 were reviewed as full-text articles, 
and 56
21–76 (representing 49 unique RCTs) were included 
in this review (Fig. 1). All included studies were obtained 
from  peer-reviewed  journals,  with  the  exception  of  2 
conference abstracts.
75,76 No evidence was found for pa-
tients switching therapy because of metformin intoler-
ance, nor were there any studies involving children. 
arms in which second-line agents were administered at 
doses below World Health Organization Defined Daily 
Doses were excluded from meta-analyses; the robust-
ness of this approach was tested through an alternate, 
dose-stratified model that included all evidence. All an-
alyses were conducted as random effects models; fixed 
effects models were tested as sensitivity analyses. Only 
pairwise comparisons were conducted for orlistat and 
sibutramine because of their specialized indications. 
WinBUGS (MRC Biostatistics Unit, Cambridge, UK) 
was used for MTC meta-analyses according to the rou-
tine developed at the universities of Bristol and Leices-
ter (www.bris.ac.uk/cobm/research/mpes/). Metformin 
monotherapy was the reference group for 
all  MTC  analyses.  Posterior  densities  for 
unknown parameters were estimated using 
Markov chain Monte Carlo methods. Basic 
parameters  were  assigned  non-informa-
tive or vague prior distributions. Point es-
timates  and  95%  credible  intervals  were 
used to summarize all findings. The prob-
ability  of  a  drug  class  being  optimal  was 
estimated  for  each  outcome  on  the  basis 
of the proportion of Markov chain Monte 
Carlo  simulations  in  which  its  relative 
measure of effect was best. We also calcu-
lated  the  mean  rank  for  each  drug  class. 
We  assessed  consistency  between  direct 
and  indirect  evidence  by  comparing  dir-
ect estimates obtained from pairwise me-
ta-analysis  with  estimates  from  the  MTC 
meta-analysis. As well, we formally tested 
for  inconsistency  using  a  function  (http://
users.uoi.gr/hyepilab/assets/pdfs/help%20
on%20MTcoherence.fun.pdf)  that  assesses 
each closed loop of the network according 
to the method of Bucher.
19 Model diagnos-
tics  including  trace  plots  and  the  Brooks-
Gelman-Rubin  statistic
20  were  assessed  to 
ensure model convergence. Two chains were 
fit in WinBUGS for each analysis, each em-
ploying ≥ 20 000 iterations, with a burn-in 
of ≥ 20 000 iterations.
We conducted meta-regression to adjust 
for baseline HbA1c, duration of diabetes and 
baseline body mass index (for body weight 
only) to test the robustness of our reference 
case analysis. In other sensitivity analyses, 
we removed studies of the following types 
from  the  network:  studies  that  were  of 
poor  methodological  quality,  studies  that 
Records identifi  ed through 
database searching  n = 3461
RCTs (full-text articles) included in meta-analysis  n = 40 
 Records excluded  n = 2455
Full-text articles excluded  n = 232
•  population not of interest  n = 145
•  study design not of interest  n = 44
•  intervention not of interest  n = 11
•  outcome not of interest  n = 3
•  duplicate data  n = 7
•  duplicate publication  n = 22
RCTs included in qualitative synthesis  n = 54
•  full-text articles  n = 49
•  abstracts  n = 2
Records screened  n = 2743
Records identifi  ed through other searches  n = 487
•  grey literature (n = 107)
•  conference abstracts (n = 209)
•  stakeholder feedback (n =13)
•  database alerts (158)
Records after duplicates 
removed  n = 2256
Full-text articles assessed for eligibility  n = 288
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The  most  common  of  these  was  inadequate  control 
with  metformin  monotherapy  under  routine  clinical 
care,  abstention  from  use  of  other  antihyperglycemic 
agents for a certain period (usually 3 months) before 
screening  and  an  unspecified  prior  treatment  his-
tory.
21–29,32,33,36,37,39,40,42–46,48,50–53,55,56,59–62,65–77 In 
the second scenario, patients using various oral anti-
hyperglycemic drugs underwent a run-in period with 
metformin  monotherapy  upon  trial  entry  and  were 
randomly  assigned  to  receive  add-on  therapy  if  gly-
cemic  control  was  inadequate  at  the  end  of  the  run-
in.
30,35,38,41,47,49,57,58,63,64  Only  one  RCT
31  reported 
inclusion criteria that probably limited the study sample 
to individuals experiencing inadequate control on initial 
Study  characteristics  and  methodological  quality. 
Most trials were 6–12 months long, although 1 study 
was  over  5  years  in  duration.  Mean  baseline  HbA1c 
ranged from 6.6% to 10% (weighted mean ± standard 
deviation  [SD]  8.0%  ±  0.9%).  The  baseline  duration 
of  diabetes  ranged  from  1.8  to  10.3  years  (weighted 
mean  ±  SD  6.1  ±  5.1  years).  The  inclusion  threshold 
for baseline HbA1c was typically 7.0%–10%; however, 
some  studies  used  thresholds  as  low  as  6.5%  or  as 
high as 11.5%. There were also differences in the dur-
ation and dosage of metformin monotherapy at base-
line, although subjects used ≥ 1500 mg for ≥ 3 months 
in many studies. Three scenarios for treatment history 
before metformin monotherapy failure were identified. 
Table 1: Summary of results from direct and mixed-treatment comparison (MTC) analyses
Hemoglobin	A1c	(change	from	baseline,	%)
Direct	estimates	 MTC	estimates
Treatment vs.	metformin	monotherapy Studies WMD (95% CI) MD (95% CrI)
Sulfonylureas 332,52,59 −0.80 (−1.00, −0.59) −0.79 (−0.95, −0.63)
Meglitinides 253,56 −0.71 (−1.24, −0.18) −0.64 (−0.93, −0.37)
TZDs 635,38,41,47,51,70 −0.96 (−1.18, −0.75) −0.82 (−1.00, −0.66)
DPP-4 Inhibitors 627,30,42,64,70,77 −0.78 (−0.96, −0.60) −0.80 (−0.95, −0.65)
AG inhibitors 543,61,67,68,72 −0.74 (−0.94, −0.53) −0.74 (−0.98, −0.50)
GLP-1 analogues 433,58,59,62 −0.75 (−0.96, −0.53) −0.82 (−1.05, −0.59)
Basal insulin — — −0.82 (−1.16, −0.47)
Biphasic insulin  — — −0.97 (−1.33, −0.61)
Overall	hypoglycemia	(odds	ratio)
Direct	estimates	 MTC	estimates
Treatment vs.	metformin	monotherapy Studies WMD (95% CI) Median OR (95% CrI)
Sulfonylureas 332,52,58 4.64 (1.27, 16.97) 8.22 (4.52, 16.63)
Meglitinides 253,56 6.59 (1.53, 28.29) 8.59 (3.47, 25.20)
TZDs 635,38,41,47,51,70 1.56 (0.56, 4.33) 1.10 (0.54, 2.27)
DPP-4 Inhibitors 727,28,30,42,64,70,77 1.07 (0.59, 1.93) 1.05 (0.56, 2.21)
AG inhibitors 268,72 0.49 (0.04, 5.55) 0.39 (0.01, 6.67)
GLP-1 analogues 133 1.00 (0.31, 3.20) 1.12 (0.33, 3.90)
Basal insulin — — 5.20 (1.48, 21.46)
Biphasic insulin  — — 11.01 (3.48, 40.43)
Body	weight	(change	from	baseline,	kg)
Direct	estimates MTC	estimates
Treatment vs.	metformin	monotherapy Studies WMD (95% CI) MD (95% CrI)
Sulfonylureas 332,52,58 1.79 (1.29, 2.28) 2.01 (1.09, 2.94)
Meglitinides 253,56 2.01 (−0.31, 4.32) 1.80 (0.35, 3.29)
TZDs 435,41,47,70 2.30 (1.93, 2.66) 2.59 (1.66, 3.51)
DPP-4 Inhibitors 327,42,70 0.70 (0.20, 1.21) 0.57 (−0.45, 1.60)
AG inhibitors 361,68,72 −0.90 (−1.92, 0.13) -0.92 (−2.35, 0.51)
GLP-1 analogues 233,58 −1.58 (−3.53, 0.37) −1.79 (−3.43, −0.14)
Basal insulin — — 1.56 (−0.46, 3.63)
Biphasic insulin  — — 2.96 (0.96, 5.00)
AG = alpha-glucosidase, CI = confi  dence interval, CrI = credible interval, DPP = dipeptidyl peptidase-4, GLP-1 = glucagon-like peptide-1,  
OR = odds ratio, TZDs = thiazolidinediones, WMD = weighted mean diff  erenceOpen Medicine 2011;5(1):e39
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metformin therapy. Most studies (89%) were 
industry funded. Complete trial and subject 
characteristics are presented in Appendices 3 
and 4 (available online).
About  two-thirds  of  the  studies  identi-
fied were of poor methodological quality (see 
Appendix  5,  available  online);  inadequate 
allocation concealment, failure to use an in-
tention-to-treat analysis and lack of blinding 
were  common  limitations.  Publication  bias 
was not assessed because of a limited num-
ber of studies for each pairwise comparison. 
Heterogeneity.  We  identified  a  number  of 
areas where there was clinical and methodo-
logical heterogeneity (Appendix 6, available 
online). Nearly all of the issues were identi-
fied  in  advance  and  were  specified  in  our 
review  protocol.
15  Overall,  meta-regression 
and sensitivity analyses yielded minimal dif-
ferences from the reference case. Therefore, 
any differences across studies in the patient 
and  trial  characteristics  assessed  had  little 
impact on the results of the analysis.
Hemoglobin AIC. Forty RCTs (n = 17 795) re-
ported change from baseline in HbA1c (Fig. 2). 
All classes of second-line agents added to met-
formin significantly reduced HbA1c relative to 
metformin alone (Table 1, Fig. 3A). Effect es-
timates ranged from −0.65% (95% confidence 
interval [CI] −1.14 to −0.20) for meglitinides 
to −0.96% (95% CI −1.57 to −0.38) for biphasic 
insulins;  there  were  no  statistically  signifi-
cant differences between drug classes. There 
was good agreement between direct pairwise 
estimates  and  MTC  estimates;  this  finding 
was confirmed through formal methods. The 
results were robust in sensitivity and meta-
regression analyses (Table 2) and in the dose-
stratified analysis.
78 In addition to grouping 
second-line  agents  by  drug  class,  we  con-
structed an additional MTC evidence network 
that  separated  the  thiazolidinedione  (TZD) 
and sulfonylurea classes into their respective 
individual agents. Specifically, the TZD class 
was split into pioglitazone and rosiglitazone, 
and the sulfonylurea class was split into gly-
buride, gliclazide, glipizide and glimepiride. 
All agents  resulted  in  a statistically  signifi-
cant reduction in HbA1c relative to placebo, 
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Figure	2: Network diagrams showing the distribution of evidence for each of the 
mixed-treatment comparison meta-analyses. Numbers denote number of random-
ized controlled trials (RCTs). (A) 40 RCTs (n = 17 795) reported change from baseline 
in hemoglobin A1c. (B) 30 RCTs (n = 15 265) reported change from baseline in body 
weight. (C) 34 RCTs (n = 16 704) reported the numbers of patients experiencing at 
least one event of overall hypoglycemia.Open Medicine 2011;5(1):e40
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Severe hypoglycemia was typically defined in the in-
cluded  trials  as  a  hypoglycemic  episode  requiring  the 
assistance of a third party. This outcome, reported in 24 
RCTs (n = 8650), was rare for all drug classes, including 
insulins and insulin secretagogues. Most trials reported 
zero  event  rates.  On  the  basis  of  the  limited  evidence 
available, neither sulfonylureas
32,52,58 (n = 501) nor GLP-
1  analogues
39,58,72  (n = 389)  differed  significantly  from 
metformin monotherapy, nor did GLP-1 analogues differ 
significantly from basal insulin.
22,29 One RCT
37 (n = 2789) 
reported  significantly  more  events  of  severe  hypogly-
cemia with sulfonylureas than with DPP-4 inhibitors (OR 
21.20, 95% CI 1.24–362.1). 
Nocturnal  hypoglycemia  was  reported  in  6  RCTs 
(n = 805), most of which reported zero events. No signifi-
cant differences between agents were observed.
Body weight. Thirty RCTs (n = 15 265) reported change 
from baseline body weight (Table 1, Fig. 3C). Treatment 
with sulfonylureas, meglitinides, TZDs and biphasic in-
sulin resulted in significantly greater increases in body 
weight than metformin monotherapy (range 1.8–3.0 kg), 
with  no  significant  differences  between  these  classes. 
DPP-4  inhibitors  and  alpha-glucosidase  inhibitors  did 
not  affect  body  weight.  The  only  drug  class  associated 
with no statistically significant differences between indi-
vidual agents in each class.
78 
Two studies investigated the addition of weight-loss 
agents to metformin. One RCT
23 (n = 69) reported a sig-
nificant HbA1c reduction in patients treated with met-
formin plus orlistat relative to metformin monotherapy 
(−0.93%, 95% CI −1.58 to −0.28), whereas a second RCT 
found no significant difference with sibutramine plus 
metformin.
55 
Hypoglycemia. Thirty-four RCTs (n = 16 704) reported 
the numbers of patients experiencing at least 1 event of 
overall hypoglycemia, an outcome that was variably de-
fined across trials. Relative to metformin monotherapy, 
risk was significantly elevated with insulins, sulfonyl-
ureas and meglitinides (odds ratios [ORs] were 5.2–11.0 
for insulins and 8.2 for sulfonylureas) (Table 1, Fig. 3B). 
There  were  no  significant  differences  between  these 
classes. By contrast, there was no significant increase 
in hypoglycemia risk with TZDs, alpha-glucosidase in-
hibitors,  DPP-4  inhibitors  or  GLP-1  analogues.  There 
was good agreement between direct pairwise estimates 
and MTC estimates. Results from meta-regression and 
sensitivity analyses were similar to the reference case 
(data not reported). 
Table 2: Sensitivity analyses for HbA1c —  MTC estimate of eﬀ  ect versus placebo
Analysis Sulfonylureas Meglitinides TZDs
DPP−4	
inhibitors
α−glucosidase	
inhibitors
GLP−1	
analogues Basal	insulin
Biphasic	
insulin
Random e￿  ects model v. ￿  xed e￿  ects model
Reference case: 
random eff  ects model
−0.80 
(−0.96, −0.65)
−0.64 
(−0.92, −0.38)
−0.85 
(−1.02, −0.69)
−0.77 
(−0.92, −0.64)
−0.75 
(−0.98, −0.51)
−0.82 
(−1.05, −0.60)
−0.82 
(−1.16, −0.48)
−0.97 
(−1.33, −0.62)
Reference case: 
fi  xed eff  ects model
−0.79 
(−0.87, −0.70)
−0.60 
(−0.78, −0.43)
−0.85 
(−0.94, −0.76)
−0.74 
(−0.82, −0.66)
−0.73 
(−0.92, −0.54)
−0.83 
(−0.99, −0.68)
−0.84 
(−1.09, −0.60)
−0.96 
(−1.20, −0.72)
Meta-regressions adjusting for:
Baseline HbA1c −0.82 
(−0.99, −0.65)
−0.64 
(−0.93, −0.36)
−0.83 
(−1.00, −0.66)
−0.80 
(−0.95, −0.66)
−0.75 
(−0.99, −0.51)
−0.84 
(−1.07, −0.61)
−0.89 
(−1.26, −0.52)
−1.00 
(−1.36, −0.63)
Baseline duration 
of diabetes
−0.81 
(−0.98, −0.64)
−0.65 
(−0.95, −0.37)
−0.81 
(−0.99, −0.64)
−0.80 
(−0.95, −0.65)
−0.72 
(−0.97, −0.47)
−0.86 
(−1.11, −0.61)
−0.87 
(−1.26, −0.49)
−0.97 
(−1.34, −0.60)
Sensitivity analyses with removal of:
Poor quality studies −0.87 
(−1.35, −0.43)
−0.71 
(−1.24, −0.24)
−0.83 
(−1.46, −0.27)
−0.78 
(−1.54, −0.02)
−0.73 
(−1.23, −0.24)
−0.90 
(−1.67, −0.14)
−0.95 
(−2.05, 0.15)
−1.07 
(−1.99, −0.20)
Cross−over studies −0.79 
(−0.96, −0.63)
−0.65 
(−0.94, −0.37)
−0.82 
(−1.00, −0.65)
−0.80 
(−0.95, −0.65)
−0.75 
(−0.99, −0.51)
−0.83 
(−1.07, −0.59)
−0.79 
(−1.21, −0.36)
−0.95 
(−1.35, −0.56)
Studies < 1 year 
in duration
−0.82 
(−1.02, −0.61)
−0.64 
(−1.02, −0.30)
−0.78 
(−0.98, −0.60)
−0.80 
(−0.97, −0.64)
−0.74 
(−1.00, −0.48)
−0.82 
(−1.06, −0.58)
−0.87 
(−1.28, −0.46)
−1.02 
(−1.42, −0.62)
Studies with < 1500 
mg/day of metformin 
at baseline
−0.83 
(−1.04, −0.63)
−0.67 
(−0.99, −0.36)
−0.86 
(−1.13, −0.60)
−0.79 
(−0.97, −0.62)
−0.74 
(−1.02, −0.46)
−0.90 
(−1.27, −0.52)
−0.88 
(−1.31, −0.44)
−1.03 
(−1.45, −0.61)
Studies < 3 months 
in duration
−0.83 
(−1.00, −0.67)
−0.66 
(−0.95, −0.38)
−0.85 
(−1.03, −0.68)
−0.81 
(−0.96, −0.67)
−0.74 
(−0.99, −0.50)
−0.90 
(−1.25, −0.56)
−0.89 
(−1.28, −0.50)
−1.02 
(−1.40, −0.65)
Studies with agents 
not sold in Canada
−0.82 
(−1.04, −0.61)
−0.67 
(−0.99, −0.37)
−0.88 
(−1.11, −0.67)
−0.73 
(−0.97, −0.51)
−0.85 
(−1.14, −0.55)
  —
−0.87 
(−1.52, −0.23)
−1.02 
(−1.55, −0.50)
HbA1c – glycosylated hemoglobin, TZD − thiazolidinediones, DPP−4 – dipeptidyl peptidase−4, GLP−1 – glucagon−like peptide−1Open Medicine 2011;5(1):e41
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A Favours
treatment
Favours
placebo
Favours
treatment
Favours
placebo
Sulfonylureas                             −0.79 (−0.95, −0.63)
Meglitinides                               −0.64 (−0.93, −0.37)
Thiazolidinediones                  −0.82 (−1.00, −0.66)
DPP-4 inhibitors                       −0.80 (−0.95, −0.65)
α-glucosidase inhibitors        −0.74 (−0.98, −0.50)
GLP-1 analogues                      −0.82 (−1.05, −0.59)
Basal insulin                               −0.82 (−1.16, −0.47)
Biphasic insulin                        −0.97 (−1.33, −0.61)
−2.0            −1.5           −1.0            −0.5                 0                0.5
Di‡erence in change from baseline in HbA1c (%, 95% CI)
B
Treatment                                   MTC estimate (95% CrI)
Treatment                                   MTC estimate (95% CrI)
Sulfonylureas                                8.22 (4.5,16.63)
Meglitinides                                  8.59 (3.34, 25.20)
Thiazolidinediones                      1.10 (0.54, 2.27)
DPP-4 inhibitors                           1.05 (0.56, 2.21)
α-glucosidase inhibitors            0.39 (0.01, 6.67)
GLP-1 analogues                          1.12 (0.33, 3.90)
Basal insulin                                  5.20 (1.48, 21.46)
Biphasic insulin                          11.02 (3.48, 40.43)
Sulfonylureas                               2.01 (1.09, 2.94)
Meglitinides                                 1.80 (0.35, 3.29)
Thiazolidinediones                     2.59 (1.66, 3.51)
DPP-4 inhibitors                          0.57 (−0.45 to 1.60)
α-glucosidase inhibitors
GLP-1 analogues                      −1.79 (−3.43, −0.14)     
Basal insulin                                 1.56 (−046, 3.63)    
Biphasic insulin                           2.96 (0.96, 5.00)
Favours
treatment
Favours
placebo Treatment                                   MTC estimate (95% CI)
Di‡erence in change from baseline in body weight kg (95% CI)
Log median odds ratio (95% CI)
0.001             0.01              0.1                 1                  10                100
–5.0                   –2.5                      0                        2.5                   5. 0              
C
−0.92 (−2.35, 0.51)
Figure	3:	Mixed-treatment comparison results showing the effect of adding second-line antihyperglycemic agents versus placebo 
in adults taking metformin on (A) change from baseline in hemoglobin A1c; (B) odds of at least 1 event of overall hypoglycemia; (C) 
change from baseline in body weight.Open Medicine 2011;5(1):e42
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inadequately  controlled  with  metformin  monotherapy. 
To our knowledge, this analysis is the first to synthesize 
the available efficacy and safety data on all therapies for 
T2DM through Bayesian MTC meta-analysis. This ap-
proach combines direct and indirect evidence in a single 
analysis that enables simultaneous comparison of mul-
tiple treatment interventions in a clinically interpretable 
manner.
18,79–81 
Our results for HbA1c, hypoglycemia and body weight 
are generally consistent with other systematic reviews 
of oral antihyperglycemic drugs.
10–14,82 All drug classes 
significantly reduced HbA1c relative to placebo to a simi-
lar degree. In some instances, our estimates of effect on 
HbA1c are somewhat lower than in other reviews. This 
may be due to our restricted focus on efficacy in the con-
text of second-line therapy, because patients requiring 
second-line therapy may have more advanced diabetes 
and  experience  smaller  treatment  effects  than  treat-
ment-naïve patients. However, our findings are similar 
to those reported by Phung and colleagues,
82 who re-
cently used MTC meta-analysis to assess the compara-
tive efficacy of oral antihyperglycemic drugs added to 
metformin.  Sulfonylureas,  meglitinides,  TZDs  and  in-
sulins were associated with statistically significant in-
creases in body weight ranging from approximately 2 kg 
to 3 kg relative to metformin alone. DPP-4 inhibitors and 
alpha-glucosidase  inhibitors  were  found  to  not  affect 
body weight, and GLP-1 analogues were associated with 
a statistically significant reduction in body weight of just 
under 2 kg. There are no well-accepted thresholds for the 
minimal weight change considered clinically significant, 
although  weight  reductions  of  5%–10%  (i.e.,  3.5–7  kg 
for a 70-kg adult) are cited as such in the literature.
83–88 
In this context, the differences in body weight that we 
observed between classes are probably modest for most 
patients. 
Both  insulins  and  insulin  secretagogues  produced 
significantly increased hypoglycemia relative to placebo, 
whereas the TZDs, DPP-4 inhibitors, GLP-1 analogues 
and alpha-glucosidase inhibitors did not. Severe hypo-
glycemia events were rarely reported for all drug classes, 
including the insulins and insulin secretagogues. Large 
observational studies and long-term RCTs provide fur-
ther insight into the risk of severe hypoglycemia among 
individuals  with  T2DM,  although  estimates  vary  con-
siderably. Leese and colleagues reported 0.90 and 11.8 
events  that  required  emergency  medical  care  per  100 
patient-years  with  insulin  secretagogues  and  insulin, 
respectively,
89 whereas Bodmer and colleagues reported 
rates of 0.06 and 0.24 events that caused either hospital-
ization or death per 100 patient-years.
90 In comparison, 
with a significant reduction in body weight versus met-
formin monotherapy was GLP-1 analogues (−1.77 kg, 95% 
CI −3.40 to −0.15). A meta-regression adjusting for differ-
ences in baseline body mass index and other sensitivity 
analyses generated results that were similar to the refer-
ence case (data not shown). There was excellent align-
ment between the direct pairwise estimates and the MTC 
results, which was confirmed through formal methods.
Both  sibutramine
55  and  orlistat
23  combined  with 
metformin were associated with significant reductions 
in body weight of 4 to 5 kg versus metformin alone. 
Long-term complications and severe adverse events. 
Most RCTs included in this review were of inadequate 
size or duration to detect differences in the occurrence 
of  long-term  complications  of  diabetes.  On  the  basis 
of the sparse data available, no significant differences 
between treatments were found (Appendix 7, available 
online). The RECORD trial, which compared metformin 
and rosiglitazone versus metformin and sulfonylurea, 
is noteworthy as the only RCT powered to detect differ-
ences in macrovascular complications.
46 Unfortunately, 
much of these data could not be included in this review 
because the results were not stratified by type of mono-
therapy at baseline.
Twenty-three  RCTs  (n = 11 933)
24,26,27,29,30,32,37,38,41,42,
47,51,52,57,60,61,63,64,66,70–72,77 reported  total  severe  adverse 
events; however, this outcome was rarely defined. Pair-
wise  meta-analysis  of  3  RCTs
24,26,70 (n = 3383)  demon-
strated a statistically significant increase in the number 
of severe adverse events for patients treated with TZDs in 
comparison with DPP-4 inhibitors (OR 1.71, 95% CI 1.06–
2.77).  No  significant  differences  were  observed  for  the 
other 9 pairwise comparisons, although statistical power 
was limited because of low event rates (data not shown). 
Quality of life and patient satisfaction. One RCT
51 com-
paring TZDs with placebo reported no significant differ-
ences in either the physical or mental components of the 
SF-36 questionnaire or Diabetes Treatment Satisfaction 
Questionnaire (DTSQ) scores. A 3-arm RCT
75 compar-
ing metformin with sulfonylurea, metformin with GLP-
1 analogue, and metformin alone reported statistically 
significant improvements in favour of metformin with 
liraglutide (a GLP-1 analogue) over the other 2 arms on 
the “perceived frequency hyperglycemia” sub-scores of 
the DTSQ. 
Discussion
We identified 49 RCTs comparing the effects of 8 anti-
hyperglycemic  drug  classes  in  patients  with  T2DM Open Medicine 2011;5(1):e43
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limited and inconclusive. A recent systematic review of 
DPP-4 inhibitors reported that no definite conclusions 
can be made regarding their effects on beta-cell func-
tion.
12  In  contrast,  A  Diabetes  Outcome  Progression 
Trial (ADOPT) reported a statistically significant differ-
ence in the number of patients experiencing monother-
apy failure, with a lower failure rate for TZDs than for 
sulfonylureas and metformin.
101 The progressive nature 
of T2DM means that many patients will eventually re-
quire insulin therapy to maintain glycemic control. In 
this context, oral agents that are capable of producing 
longer periods of sustained glycemic control could delay 
initiation of insulin initiation, which may be desirable for 
some patients and could result in cost savings, given the 
expense of insulin therapy. We could find no conclusive 
evidence  that  TZDs  and  incretin  mimetics  have  more 
durable effects on glycemia than sulfonylureas. Further 
long-term studies are needed to explore differences in 
glycemic durability between agents over time, especially 
for the newer, more expensive oral antidiabetes drugs. 
Strengths and limitations. The strengths of our analysis 
were its comprehensiveness in terms of the drug classes 
considered, the number of outcomes assessed and the 
use  of  MTC  meta-analyses  incorporating  both  direct 
and indirect evidence in a clinically interpretable man-
ner. However, certain limitations also deserve mention. 
First, potentially relevant non-English studies may have 
been excluded, although restriction to English-language 
studies has been reported to have minimal impact on 
systematic  review  results.
102–105  Second,  we  did  not 
assess non-serious adverse effects that can affect the 
tolerability of antihyperglycemic agents. For example, 
acarbose is commonly associated with gastrointestinal 
adverse effects that may limit its usefulness.
61 Third, 
inclusion of insulin in the MTC meta-analysis may be 
viewed  with  scepticism  because  it  is  not  commonly 
considered as second-line therapy after metformin in 
clinical practice and because trials of insulin may have 
enrolled  patients  with  more  advanced  or  severe  dis-
ease than trials of oral agents. However, we believed it 
important to quantify the effects of insulin relative to 
other  antihyperglycemic  agents  so  that  patients  and 
clinicians  can  make  informed  choices  regarding  all 
available treatment options. Furthermore, scrutiny of 
subject  characteristics  revealed  no  major  differences 
between the subjects enrolled in insulin trials and trials 
of other agents. Meta-regression analyses to adjust for 
differences in baseline HbA1c and duration of diabetes 
produced  results  that  were  similar  to  the  reference 
case;  therefore,  any  differences  in  these  parameters 
the ADVANCE trialists reported lower incidence rates 
than Leese and colleagues (0.7 per 100 patient-years in 
the intensive glycemic control arm versus 0.4 per 100 
patient-years in the standard control arm), even though 
they defined severe hypoglycemia more liberally (i.e., 
medical resource use was not required).
91 In the RE-
CORD study, only 0.3% of subjects in the control arm 
(all of whom used metformin and a sulfonylurea) ex-
perienced a severe hypoglycemic event over the 5.5-year 
mean follow-up of the study.
46 Overall, it appears that 
the  risk  of  severe  hypoglycemia  with  insulin  secreta-
gogues is quite low; therefore, any advantages of TZDs, 
GLP-1  analogues  and  DPP-4  inhibitors  are  probably 
modest in absolute terms. Further research is required 
to determine whether these agents provide greater bene-
fits in patient groups at higher risk of severe hypogly-
cemia or its consequences. 
Evidence regarding long-term diabetes-related com-
plications and severe adverse events was inconclusive. 
The RECORD trial was the only included study powered 
to detect differences in long-term complications.
46 Al-
though we could not include these results in the review 
because of the lack of subgroup data for subjects initially 
taking metformin monotherapy, the overall results from 
RECORD  are  nevertheless  noteworthy.  Rosiglitazone 
was found to be non-inferior to the control treatment 
with respect to the primary macrovascular outcome of 
cardiovascular  death  or  hospitalization,  but  the  drug 
was associated with a significantly higher risk of heart 
failure and fractures. The data on fractures and heart 
failure were consistent with past studies,
11,92,93 although 
controversy remains regarding the effects of TZDs on 
the risk of ischemic heart disease.
94 The safety profile 
of the newest drug classes (i.e., DPP-4 inhibitors, GLP-1 
analogues) requires further study in long-term obser-
vational studies and RCTs although there is evidence, 
albeit  inconsistent,  that  they  may  be  associated  with 
pancreatitis.
95,96 Advantages of older drug classes such 
as sulfonylureas and insulin are the availability of trial 
data regarding long-range safety
97,98 and the extensive 
clinical experience with these agents.
Long-term studies such as the United Kingdom Pro-
spective  Diabetes  Study  (UKPDS)  have  convincingly 
demonstrated  a  progressive  time-dependent  increase 
in the HbA1c levels of patients with T2DM.
99,100 This 
gradual loss of glycemic control is primarily attribut-
able to a corresponding decrease in pancreatic beta-cell 
function. There is speculation that newer agents such as 
DPP-4 inhibitors, GLP-1 analogues and TZDs can offer 
the benefit of prolonged glycemic control by slowing the 
decline of beta-cell function; however, the evidence is Open Medicine 2011;5(1):e44
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